Brind.
  1. GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.
  2. Moderna's vaccine demonstrated superior efficacy compared to GSK's flu shot on July 1, 2025.

Positive test results were reported for Moderna's flu vaccine.

2 reports, 1 independent Updated Sep 2
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Positive test results were reported for Moderna's flu vaccine.

Who's involved

What this event is mainly about
Moderna

How it developed

Newest first. Tap a step to see who reported it.
  1. Positive late-stage trial results reported for Moderna's mRNA vaccine.1 source
  2. Specific positive test results for the Moderna flu vaccine were reported.

Keep exploring

Part of

Moderna's vaccine demonstrated superior efficacy compared to GSK's flu shot on July 1, 2025. All 1 developments

Within GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.

The entities involved

Related events

Coverage

Newest first; wire copies grouped